Suppr超能文献

肿瘤学临床试验的终点指标。

Endpoints in oncology clinical trials.

作者信息

Kilickap Saadettin, Demirci Umut, Karadurmus Nuri, Dogan Mutlu, Akinci Bulent, Sendur Mehmet Ali Nahit

机构信息

Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.

出版信息

J BUON. 2018 Dec;23(7):1-6.

Abstract

In oncology clinical trials, many different endpoints can be used as primary or secondary endpoints. Advances in cancer treatment have provided longer survival outcomes, particularly in certain types of cancer. Overall survival is accepted as the gold standard endpoint for demonstrating clinical benefit; however, it is associated with some disadvantages such as requirement of long-term follow-up, requirement of higher number of patients, and high cost. Thus, the question "what is the most appropriate endpoint in clinical trials?" comes to mind. The present review discusses the endpoints in oncology clinical trials.

摘要

在肿瘤学临床试验中,许多不同的终点指标可作为主要或次要终点。癌症治疗的进展带来了更长的生存结果,尤其是在某些类型的癌症中。总生存期被公认为证明临床获益的金标准终点指标;然而,它也存在一些缺点,如需要长期随访、需要更多患者以及成本高昂。因此,“临床试验中最合适的终点指标是什么?”这个问题便浮现出来。本综述讨论了肿瘤学临床试验中的终点指标。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验